Nomogram models predicting prognosis for patients with t(8;21) acute myeloid leukemia: a SEER-based study
Jiapeng Yang,
Xiaohua Zhu,
Honghong Zhang,
Yang Fu,
Zifeng Li,
Ziping Xing,
Yi Yu,
Ping Cao,
Jun Le,
Junye Jiang,
Jun Li,
Hongsheng Wang,
Maoxiang Qian,
Xiaowen Zhai
Affiliations
Jiapeng Yang
Department of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, People’s Republic of China
Xiaohua Zhu
Department of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, People’s Republic of China
Honghong Zhang
Department of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, People’s Republic of China
Yang Fu
Department of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, People’s Republic of China
Zifeng Li
Department of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, People’s Republic of China
Ziping Xing
Department of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, People’s Republic of China
Yi Yu
Department of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, People’s Republic of China
Ping Cao
Department of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, People’s Republic of China
Jun Le
Department of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, People’s Republic of China
Junye Jiang
Department of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, People’s Republic of China
Jun Li
Department of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, People’s Republic of China
Hongsheng Wang
Department of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, People’s Republic of China
Maoxiang Qian
Institute of Pediatrics and Department of Hematology and Oncology, Children's Hospital of Fudan University, National Children's Medical Center, and the Shanghai Key Laboratory of Medical Epigenetics, International Co-Laboratory of Medical Epigenetics and Metabolism (Ministry of Science and Technology), Institutes of Biomedical Sciences, Fudan University, Shanghai, People’s Republic of China
Xiaowen Zhai
Department of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, People’s Republic of China
Background: Acute myeloid leukemia (AML) with t(8;21) manifests as a diverse hematological malignancy. Although it was categorized into a favorable subtype, 30–40% of patients experience relapse. The objective of this research was to devise a nomogram for the accurate anticipation of both overall survival (OS) and cancer-specific survival (CSS) in t(8;21) AML.Methods: From the Surveillance, Epidemiology, and End Results (SEER) database, individuals diagnosed with t(8;21) AML from 2000 to 2018 were selected. Prognostic factors for t(8;21) AML were identified using Cox regression analysis and Akaike Information Criterion (AIC), forming the basis for constructing prognostic nomograms.Results: Key variables, including first primary tumor, age group, race, and chemotherapy, were identified and integrated into the nomogram. The C-index values for the nomograms predicting OS and CSS were 0.753 (validation: 0.765) and 0.764 (validation: 0.757), respectively. Ultimately, based on nomogram scores, patients were stratified into high-risk and low-risk groups, revealing significant disparities in both OS and CSS between these groups (P < 0.001).Conclusion: This study innovatively crafted nomograms, incorporating clinical and therapeutic variables, to forecast the 1-, 3-, and 5-year survival rates for individuals with t(8;21) AML.
